# West Pharmaceutical Services Inc: overview

WST · NYSE · CIK 105770 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wst.md) · [Financials](/companies/wst/financials.md) · [Filings](/companies/wst/filings.md) · [Insiders](/companies/wst/insiders.md)

Latest reported revenue: [$874.5m](/filings/0000105770-26-000121.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000105770-26-000121).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [749 d](/filings/0000105770-26-000010.md) | [698](/filings/0000105770-26-000049.md) | [767](/filings/0000105770-26-000099.md) | [805](/filings/0000105770-26-000121.md) | [805 d](/filings/0000105770-26-000010.md) | [845](/filings/0000105770-26-000049.md) | [872](/filings/0000105770-26-000099.md) | [875](/filings/0000105770-26-000121.md) |
| Gross margin | % | [36.5% d](/filings/0000105770-26-000010.md) | [33.2%](/filings/0000105770-26-000049.md) | [35.7%](/filings/0000105770-26-000099.md) | [36.6%](/filings/0000105770-26-000121.md) | [37.8% d](/filings/0000105770-26-000010.md) | [35.1%](/filings/0000105770-26-000049.md) | [37.7%](/filings/0000105770-26-000099.md) | [39.7%](/filings/0000105770-26-000121.md) |
| Operating margin | % | [21.3% d](/filings/0000105770-26-000010.md) | [15.3%](/filings/0000105770-26-000049.md) | [20.1%](/filings/0000105770-26-000099.md) | [20.8%](/filings/0000105770-26-000121.md) | [19.5% d](/filings/0000105770-26-000010.md) | [21.0%](/filings/0000105770-26-000049.md) | [20.5%](/filings/0000105770-26-000099.md) | [30.6%](/filings/0000105770-26-000121.md) |
| Net margin | % | [17.4% d](/filings/0000105770-26-000010.md) | [12.9%](/filings/0000105770-26-000121.md) | [17.2%](/filings/0000105770-26-000121.md) | [17.4%](/filings/0000105770-26-000121.md) | [16.4% d](/filings/0000105770-26-000010.md) | [16.4%](/filings/0000105770-26-000121.md) | [17.7%](/filings/0000105770-26-000121.md) | [24.5%](/filings/0000105770-26-000121.md) |
| Diluted EPS | $ per share | not reported | [1.23](/filings/0000105770-26-000049.md) | [1.82](/filings/0000105770-26-000099.md) | [1.92](/filings/0000105770-26-000121.md) | not reported | [1.92](/filings/0000105770-26-000049.md) | [2.15](/filings/0000105770-26-000099.md) | [3.02](/filings/0000105770-26-000121.md) |
| Free cash flow | $m | [85.2 d](/filings/0000105770-26-000010.md) | [58.1](/filings/0000105770-26-000049.md) | [102 d](/filings/0000105770-26-000099.md) | [134 d](/filings/0000105770-26-000121.md) | [175 d](/filings/0000105770-26-000010.md) | [47.2](/filings/0000105770-26-000049.md) | [80.8 d](/filings/0000105770-26-000099.md) | [150 d](/filings/0000105770-26-000121.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,832](/filings/0000105770-24-000015.md) | [2,887](/filings/0000105770-25-000013.md) | [2,950](/filings/0000105770-26-000010.md) | [2,893](/filings/0000105770-26-000010.md) | [3,074](/filings/0000105770-26-000010.md) |
| Gross margin | % | [41.5%](/filings/0000105770-24-000015.md) | [39.4%](/filings/0000105770-25-000013.md) | [38.3%](/filings/0000105770-26-000010.md) | [34.5%](/filings/0000105770-26-000010.md) | [35.9%](/filings/0000105770-26-000010.md) |
| Operating margin | % | [26.6%](/filings/0000105770-24-000015.md) | [25.4%](/filings/0000105770-25-000013.md) | [22.9%](/filings/0000105770-26-000010.md) | [19.7%](/filings/0000105770-26-000010.md) | [19.0%](/filings/0000105770-26-000010.md) |
| Net margin | % | [23.4%](/filings/0000105770-24-000015.md) | [20.3%](/filings/0000105770-25-000013.md) | [20.1%](/filings/0000105770-26-000010.md) | [17.0%](/filings/0000105770-26-000010.md) | [16.1%](/filings/0000105770-26-000010.md) |
| Diluted EPS | $ per share | [8.67](/filings/0000105770-24-000015.md) | [7.73](/filings/0000105770-25-000013.md) | [7.88](/filings/0000105770-26-000010.md) | [6.69](/filings/0000105770-26-000010.md) | [6.79](/filings/0000105770-26-000010.md) |
| Free cash flow | $m | [331](/filings/0000105770-24-000015.md) | [439](/filings/0000105770-25-000013.md) | [415](/filings/0000105770-26-000010.md) | [276](/filings/0000105770-26-000010.md) | [469](/filings/0000105770-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/wst/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.39bn | 6,651,784 |  | Reduced −184,930 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.66bn | 4,613,134 |  | Reduced −70,152 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.44bn | 4,015,766 |  | Reduced −78,243 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.28bn | 3,574,816 |  | Added +2,325,068 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.20bn | 3,348,698 |  | Added +54,920 |
| [Artisan Partners Limited Partnership](/funds/1466153.md) | 2026-06-30 | $865.8m | 2,411,792 |  | Reduced −246,101 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $733.7m | 2,043,823 |  | Reduced −422,035 |
| [GENERATION INVESTMENT MANAGEMENT LLP](/funds/1375534.md) | 2026-06-30 | $728.2m | 2,028,322 |  | Reduced −215,654 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $680.6m | 1,903,279 |  | Reduced −9,176 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $568.1m | 1,582,546 |  | Added +124,264 |

## Recent filings

[All 1,721 filings](/companies/wst/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:17 ET | [10-Q](/filings/0000105770-26-000121.md) | Quarterly report, period 2026-09-30 | 0000105770-26-000121 |
| 2026-10-29 | 07:06 ET | [8-K](/filings/0000105770-26-000118.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000105770-26-000118 |
| 2026-10-26 | 17:14 ET | [8-K](/filings/0000105770-26-000114.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000105770-26-000114 |
| 2026-07-23 | 16:15 ET | [10-Q](/filings/0000105770-26-000099.md) | Quarterly report, period 2026-06-30 | 0000105770-26-000099 |
| 2026-07-23 | 07:14 ET | [8-K](/filings/0000105770-26-000097.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000105770-26-000097 |
| 2026-07-14 | 16:29 ET | [8-K](/filings/0000105770-26-000093.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000105770-26-000093 |
| 2026-06-01 | 16:32 ET | [8-K](/filings/0000105770-26-000080.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000105770-26-000080 |
| 2026-05-20 | 16:04 ET | [8-K/A](/filings/0000105770-26-000077.md) | 1.05 Material cybersecurity incident; 9.01 Financial statements and exhibits | 0000105770-26-000077 |
| 2026-05-11 | 17:06 ET | [8-K](/filings/0000105770-26-000068.md) | 1.05 Material cybersecurity incident; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000105770-26-000068 |
| 2026-05-05 | 16:49 ET | [8-K](/filings/0000105770-26-000056.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000105770-26-000056 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000105770-26-000010.md), filed Feb 17, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/da318ff4-2be5-4fdd-bbdc-f87253e31207)

## About the filer

- CIK: 105770
- Tickers: WST
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: PA
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:13 ET. No prices; not investment advice.